Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
Trophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was wid...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1744 |
| _version_ | 1797613023530057728 |
|---|---|
| author | Pasquale Lombardi Marco Filetti Rosa Falcone Valeria Altamura Francesco Paroni Sterbini Emilio Bria Alessandra Fabi Diana Giannarelli Giovanni Scambia Gennaro Daniele |
| author_facet | Pasquale Lombardi Marco Filetti Rosa Falcone Valeria Altamura Francesco Paroni Sterbini Emilio Bria Alessandra Fabi Diana Giannarelli Giovanni Scambia Gennaro Daniele |
| author_sort | Pasquale Lombardi |
| collection | DOAJ |
| description | Trophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was widely recognized and clinical studies with drug–antibody conjugates have been initiated in various cancer types. Recently, these efforts have been rewarded with the approval of sacituzumab govitecan from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA), for metastatic triple-negative breast cancer patients. In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy in current clinical practice. We also review the ongoing clinical trials to provide a snapshot of the future developments of these therapies. |
| first_indexed | 2024-03-11T06:49:07Z |
| format | Article |
| id | doaj.art-e53372f485c148438b1e8e636eac576d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:49:07Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e53372f485c148438b1e8e636eac576d2023-11-17T10:06:36ZengMDPI AGCancers2072-66942023-03-01156174410.3390/cancers15061744Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical SettingsPasquale Lombardi0Marco Filetti1Rosa Falcone2Valeria Altamura3Francesco Paroni Sterbini4Emilio Bria5Alessandra Fabi6Diana Giannarelli7Giovanni Scambia8Gennaro Daniele9Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyPhase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyPhase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyPhase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyPhase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyPrecision Medicine in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyFacility of Epidemiology and Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyDepartment of Life Science and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, ItalyPhase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyTrophoblast cell surface antigen-2 (Trop-2) is a glycoprotein that was first described as a membrane marker of trophoblast cells and was associated with regenerative abilities. Trop-2 overexpression was also described in several tumour types. Nevertheless, the therapeutic potential of Trop-2 was widely recognized and clinical studies with drug–antibody conjugates have been initiated in various cancer types. Recently, these efforts have been rewarded with the approval of sacituzumab govitecan from both the Food and Drug Administration (FDA) and European Medicines Agency (EMA), for metastatic triple-negative breast cancer patients. In our work, we briefly summarize the various characteristics of cancer cells overexpressing Trop-2, the pre-clinical activities of specific inhibitors, and the role of anti-Trop-2 therapy in current clinical practice. We also review the ongoing clinical trials to provide a snapshot of the future developments of these therapies.https://www.mdpi.com/2072-6694/15/6/1744Trop-2ADCtarget therapybystander effect |
| spellingShingle | Pasquale Lombardi Marco Filetti Rosa Falcone Valeria Altamura Francesco Paroni Sterbini Emilio Bria Alessandra Fabi Diana Giannarelli Giovanni Scambia Gennaro Daniele Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings Cancers Trop-2 ADC target therapy bystander effect |
| title | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings |
| title_full | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings |
| title_fullStr | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings |
| title_full_unstemmed | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings |
| title_short | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings |
| title_sort | overview of trop 2 in cancer from pre clinical studies to future directions in clinical settings |
| topic | Trop-2 ADC target therapy bystander effect |
| url | https://www.mdpi.com/2072-6694/15/6/1744 |
| work_keys_str_mv | AT pasqualelombardi overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT marcofiletti overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT rosafalcone overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT valeriaaltamura overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT francescoparonisterbini overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT emiliobria overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT alessandrafabi overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT dianagiannarelli overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT giovanniscambia overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings AT gennarodaniele overviewoftrop2incancerfrompreclinicalstudiestofuturedirectionsinclinicalsettings |